Growth stocks have performed surprisingly well in 2023. Despite ever-rising interest rates, a possible recession, and a regional banking crisis, the growth-oriented Nasdaq Composite has ticked higher by an impressive 14.8% so far this year. 

Which growth stocks ought to continue to march northward in the second quarter of the year and beyond? Innovation juggernaut CRISPR Therapeutics (NASDAQ: CRSP) has crushed the broader markets through the first four months of 2023. This trend seems likely to continue due to its underappreciated pipeline and prospects as a top buyout candidate. Read on to find out more.

Continue reading

Source Fool.com